<DOC>
	<DOCNO>NCT02955030</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity sublingual administration NSV0001 healthy male volunteer .</brief_summary>
	<brief_title>Evaluation Safety Immunogenicity Sublingual Influenza Vaccine NSV0001 Healthy Male Volunteers</brief_title>
	<detailed_description>NSV0001 quadrivalent influenza vaccine new adjuvant ( ND002 ) administer sublingual route . This study enroll healthy male adult . Participants receive two dos vaccine , 4 week apart , stay investigational site 2 consecutive day vaccination . Participants keep patient diary record local systemic reaction one week vaccination . In addition , safety monitoring extend 6 month last vaccination detect potential immune mediate disorder ( pIMD ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Subject 20 49 year age date inform consent 2 . Individuals determine eligible healthy adult participate clinical study result medical history , medical examination clinical estimation principal investigator / subinvestigator . 3 . Written inform consent obtain subject . And subject principal investigator/ subinvestigator judge following condition ; subject able follow study instruction , subject able receive medical examination test prescribe protocol subject able inform indication , etc . 4 . Individuals able receive telephone communication clinical trial participation 1 . History administration seasonal influenza HA vaccine within 180 day 2 . History infection influenza within 180 day 3 . History receive live attenuate vaccine within 28 day inactivate vaccine/ toxoid within 7 day 4 . History receive follow treatment medical drug I . Within 28 day : 1 . Interferon product , 2 . Drugs affect immune system ( e.g. , immunosuppressant ) , 3 . Systemic inhalant adrenocorticosteroid , 4 . GCSF MCSF II . Within 84 day : 1 . HGG product , 2 . Blood product , 3. blood transfusion ( include blood component transfusion ) III . Within 180 day : 1. massive dose therapy HGG product ( ≥200 mg/kg ) 5 . History previous cause anaphylaxis intake food drug ( include vaccine ) 6 . History previous finding suspect allergic reaction oral cavity , pharynx laryngeal mucosa 7 . Individuals hypersensitivity seasonal influenza HA vaccine chicken egg , chicken meat chicken derive material 8 . Individuals experience fever 39.0℃ find suspect allergic reaction e.g . generalize rash within two day previous preventive treatment ( seasonal influenza vaccine vaccine ) 9 . History anamnestic convulsion ( exclude anamnestic fever convulsion childhood ) 10 . History previously diagnosis immunodeficiency , individual close relative ( within third degree ) congenital immunodeficiency syndrome 11 . History anamnestic GuillainBarre syndrome ADE ( Acute Disseminated Encephalomyelitis ) 12 . Individuals poorly control cardiovascular , hematological , hepatic , renal , gastrointestinal , urological endocrine metabolic disease , diseases possibly affect participation clinical study study result 13 . Individuals respiratory disease e.g . interstitial pneumonia bronchial asthma 14 . Individuals associate allergic rhinitis , symptom 15 . Individuals experience whole blood donation le 400 mL within 12 week , whole blood donation le 200 mL within 4 week , apheresis within 2 week 16 . Individuals receive study medication within 4 month 17 . Individuals inflammation , swell uncomfortable feeling , mechanical problem oral cavity , sublingual , tongue , pharynx laryngeal mucosa , disturb sublingual administration affect absorption 18 . Individuals recover injury laryngeal mucosa cause treatment dental extraction etc . ( exclude treatment carious teeth ) 19 . Individuals associated disease abnormal salivation ( Sjogren 's syndrome , welldefined dry mouth / xerostomia etc . ) 20 . Individuals positive reaction STS ( serological test syphilis ) ( TP antibody , lipid antibody ) , HBs antigen , HCV antibody , HIV antigen/ antibody 21 . History anamnestic drug abuse ( defined illegal drug use ) alcoholism within one year IMP dosing , individual give consume excessive alcohol 22 . Individuals clinically problematic abnormality 12lead electrocardiogram examination 23 . Individuals find abnormal value clinical laboratory test , suggest clinically problematic complication , individual find abnormal value follow test item : ALT and/ AST 3 time upper limit standard value . 24 . In addition , individual principal investigator/ subinvestigator judge inappropriate subject clinical trial</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>